Edition:
United States

Cascadian Therapeutics Inc (CASC.OQ)

CASC.OQ on NASDAQ Stock Exchange Global Select Market

3.69USD
14 Dec 2017
Change (% chg)

$-0.16 (-4.16%)
Prev Close
$3.85
Open
$3.87
Day's High
$3.95
Day's Low
$3.60
Volume
85,055
Avg. Vol
77,256
52-wk High
$5.84
52-wk Low
$3.20

Chart for

About

Cascadian Therapeutics, Inc., formerly Oncothyreon Inc., is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company's clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth... (more)

Overall

Beta: 2.30
Market Cap(Mil.): $186.57
Shares Outstanding(Mil.): 50.56
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 196.13 16.04
EPS (TTM): -- -- --
ROI: -- -11.69 35.70
ROE: -- -36.44 15.40

BRIEF-Cascadian Therapeutics reports Q3 loss per share $0.28

* Cascadian Therapeutics reports third quarter 2017 financial results

Nov 08 2017

BRIEF-Cascadian Therapeutics announces FDA orphan drug designation granted to Tucatinib for the treatment of HER2 colorectal cancer

* Cascadian Therapeutics announces FDA orphan drug designation granted to tucatinib for the treatment of HER2+ metastatic colorectal cancer Source text for Eikon: Further company coverage:

Sep 27 2017

BRIEF-Cascadian Therapeutics Q2 loss per share $0.30

* Cascadian Therapeutics reports second quarter 2017 financial results

Aug 08 2017

BRIEF-Cascadian Therapeutics announces positive regulatory update for Tucatinib in Europe

* Cascadian Therapeutics announces positive regulatory update for tucatinib in Europe

Jul 11 2017

Competitors

Earnings vs. Estimates